Yi-Kai Lo CEO

Coming soon.

Therapeutic: Coming soon.

Ida Good CEO

Cerevia Neurosciences (Castro Valley, California USA) is developing the Ladybug™ Sanctuary, a clinic-based, NeuroAI-enabled, fMRI-guided closed-loop network neuromodulation platform for Alzheimer’s dementia. Patient and platform digital twins personalize targeting, stimulation, and treatment adaptation. Each session generates longitudinal imaging, treatment, and outcomes data, transforming therapy into intelligence that can improve care, support biomarker discovery, accelerate research, and enable expansion into additional neurologic indications.

Therapeutic: Neuromodulation-neurostimulation; Digital Health, Women's Health

Bhaskar Ramamurthy CEO

Coming soon.

Therapeutic: Coming soon.

Jodi Akin Chair

Coming soon.

Therapeutic: Coming soon.

Mike Connolly CEO

Healionics (Seattle, WA, USA) is developing safer, more reliable means of bloodstream access to support life-saving dialysis therapy in kidney failure patients. Its STARgraft AV graft shows excellent clinical resistance to both occlusion and infection -- the two primary causes of failure in on-market grafts. The company also has a diverse product pipeline leveraging its core biomaterial technology which can inhibit scar tissue encapsulation and infection to improve performance of a wide range of other implantable devices and facilitate creation of new ones.

Therapeutic: Cardiovascular; Dialysis access devices, Vascular Surgery, Biomaterials

Richard van de Wateringen CEO

IPD (Leiden, The Netherlands) is developing a medical device using induction heating technology to treat Prosthetic Joint Infections during the standard of care. By using induction technology, the implant is heated while still inside the patient- eliminating bacteria and biofilm on the implant and ultimately curing the infection.

Therapeutic: Infection Control

Joshua Reicher CEO

IMVARIA (Berkeley, CA, USA) is a leading applied clinical AI company delivering FDA-cleared services into everyday practice through a unique centralized model. We operate a CMS-approved offering in alignment with the new Software-as-a-Medical-Service (SaMS) pathway, through rapid-adoption, zero integration workflows. The platform's leading assets are Fibresolve and ScreenDx, both in high impact lung disease, driving accelerating national adoption and major patient impact across health systems, payers, and pharma partners. Our pipeline extends this model into multiple areas in oncology, with additional services in active development.

Therapeutic: Artificial Intelligence; Pulmonary

Andrew Holman Founder & CEO

Coming soon.

Therapeutic: Coming soon

Gregg Smith  CEO

Lite Run (St. Paul, MN) is a medical technology company transforming patient mobility and rehabilitation. Its FDA-registered anti-gravity mobilization system uses patented pneumatic Exosuits to safely support and unweight patients during standing and walking. Unlike traditional harness-based systems, Lite Run is mobile, comfortable, and designed for use by a single clinician. The technology helps healthcare providers mobilize patients earlier, improve therapy efficiency, reduce physical strain on staff, and support better functional recovery.

Therapeutic: Mobility In-Patient and Home

Jorge Ferrer Chief Scientific Officer

Lumicell (Waltham, MA, USA) is a commercial-stage company transforming cancer surgery through real-time, fluorescence-guided tumor detection. Its FDA-approved LumiSystem™, combining the LUMISIGHT™ (pegulicianine) plus the Lumicell Direct Visualization System, is the first and only technology enabling surgeons to detect residual cancer directly inside the breast lumpectomy cavity during surgery. Backed by established Medicare and commercial reimbursement, LumiSystem is gaining momentum with implementation at leading cancer institutions. Building on this platform, Lumicell is investigating its fluorescence-guided imaging in gastrointestinal cancers, beginning with esophageal cancer.

Therapeutic: Surgery; Surgical Oncology

Alan Lucas CEO

NaviSci (Brookline, MA) is capitalizing on the emergence of low-dose CT scanning to detect early-stage lung tumors and clinical studies demonstrating that surgical removal of less tissue in early-stage lung cancer, with appropriate margins, can be curative. The system integrates Augmented Reality (AR) and advanced software with surgical hardware to guide precise surgical resection by enabling, for the first time, real-time in vivo tissue measurement.

Therapeutic: Minimally invasive surgery; Surgical oncology

Robert Rennaker CEO

NeuWire Medical (Plano, Texas, USA) offers closed-loop, miniature, wireless vagus nerve stimulation designed to integrate recovery from stroke into daily life.

Therapeutic: Neuromodulation-neurostimulation; Chronic ischemic stroke rehabilitation

Caitlin Cameron Chair & CEO

Coming soon.

Therapeutic: Coming soon

Will Mauldin CEO

Rivanna Guidance Solutions (RGS) (Charlottesville, VA, USA) is transforming epidural placement with Accuro 3S, an FDA-cleared, AI-powered ultrasound system providing real-time anatomical and needle guidance. Epidurals still rely largely on touch, leaving patients vulnerable to repeated attempts, failed placements, and complications. Accuro 3S combines automated anatomy recognition, continuous needle tracking, and hands-free probe positioning to support precise placement. RGS targets an estimated $300 million initial market in labor and delivery within a broader $3.5 billion opportunity, advancing safer, more compassionate care for patients.

Therapeutic: Imaging; Pain Control

Stephen Belcher CEO

Secure Closure Inc. (Denver, Colorado, USA) is developing Quattro-Close™, a next-generation, suture-based large-bore vascular closure device for minimally invasive cardiovascular procedures including TAVR and EVAR. Designed as a single-device, over-the-wire solution, Quattro-Close combines four-point suture delivery with proprietary technology, including the Halo-Lock™ closure mechanism, to provide reliable, predictable closure, including in challenging anatomy. The technology aims to reduce bleeding complications, improve patient safety, simplify procedures, and lower healthcare costs.

Therapeutic category: Cardiovascular

Elaine Horn-Ranney CEO

Coming soon.

Therapeutic: Coming soon